Accuracy of screening for gastric cancer using serum pepsinogen concentrations

Gut

Volumn 44, Issue 5, 1999, Pages 693-697

  Kitahara, F ^a   Kobayashi, K ^b   Sato, T ^a   Kojima, Y ^a   Araki, T ^a   Fujino, M A ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b Health Care Centre   (Japan)

Author keywords

Atrophic gastritis; Cut off point; Gastric cancer; Pepsinogen; Receiver operator characteristics curves; Screening

Indexed keywords

PEPSINOGEN;

ARTICLE; ATROPHIC GASTRITIS; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENDOSCOPY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; JAPAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STOMACH CANCER;

EID: 0033042057     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.44.5.693     Document Type: Article

References (22)

1. 1 Webb MP, Hengels JK, Moller H, et al. The epidemiology of low serum pepsinogen A levels and an international association with gastric cancer rates. Gastroenterology 1994;107:1335-44.
2. 2 Kabuto M, Imai H, Tsugane S, et al. Correlation between atrophic gastritis prevalance and gastric cancer mortality among middle-aged men in 5 areas in Japan. J Epidemiol 1993;3:35-9.
3. 3 Fukao A, Hisamichi S, Sugawara N, et al. A case-control study on evaluating the effect of mass screening on decreasing advanced stomach cancer. Journal of Gastroenterological Mass Survey 1987;75:112-16. (In Japanese.)
4. 4 Fukao A, Tsubono Y, Tsuji I, et al. The evaluation of screening or gastric cancer in Miyagi Prefecture, Japan: a population-based case-control study. Int J Cancer 1995;60: 45-8.
5. 5 Oshima A, Hirata N, Ubukata T, et al. The effect of a mass screening program in reducing stomach cancer mortality rate: evaluation with a case-control study design. Journal of Gastroenterological Mass Survey 1986;73;47-52. (In Japanese.)
6. 6 Hamahata M, Kusano K, Sibue T, et al. The close examination methods and the accuracy of gastric mass survey. Journal of Gastroenterological Mass Survey 1993;98:3-8. (In Japanese.)
7. 7 Yoshida Y, Tamura K, Arisue T, et al. Study on controlling method of precision of the first screening of the gastric carcinoma mass survey. Journal of Gastroenterological Mass Survey 1992;97:51-8. (In Japanese.)
8. 8 Iimura T, Takeno Y. Cost-effectiveness of mass screening for stomach cancer. Journal of Gastroenterological Mass Survey 1988;79:94-100. (In Japanese.)
9. 9 Maruyama T, Noda Y, Kumamoto Y. Estimation of frequency, population doses and stochastic risks in stomach mass screening examination in Japan. Nippon Acta Radiology 1987;47:971-82. (Japanese text with English abstract.)
10. 10 Kitahara F, Kashiwagi A, Kanai T, et al. A role of pepsinogen assay as the first cancer screening before screening by gastroscopy. Journal of Gastroenterological Mass Survey 1996;116:42-8. (In Japanese.)
11. 11 Miki K. Mass screening of stomach neoplasms by serum pepsinogen analysis. Journal of the Japanese Society of Internal Medicine 1992;81:654-9.
12. 12 Miki K, Ichinose M, Ishikawa KB, et al. Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer. Jpn J Cancer Res 1993;84:1086-90.
13. 13 Kodoi A, Yoshihara M, Sumii K, et al. Serum pepsinogen in screening for gastric cancer. J Gastroenterol 1995;30:452-60.
14. 14 Samloff IM, Varis K, Ihamaki T, et al. Relationship among serum pepsinogen I, serum pepsinogen II and gastric mucosal histrogy: a study in relatives of patient with pernicious anemia Gastroenterology 1982;83:204-9.
15. 15 Kimura K, Takemoto T. An endoscopic recognization of the atrophic border and its significance in chronic gastritis. Endoscopy 1969;1:87-97.
16. 16 Sitas F, Smallwood R, Jewell D, et al. Serum anti-Helicobacter pylori IgG antibodies and pepsinogens A and C as serological markers of chronic atrophic gastritis. Cancer Epidemiology, Biomarkers and Prevention 1993;2:119-23.
17. 17 Fukao A, Hisamichi S, Ohsato N, et al. Correlation between the prevalence of gastritis and gastric cancer in Japan. Cancer Causes and Control 1993;4:17-20.
18. 18 Ichinose M, Miki K, Furihata C, et al. Radioimmunoassay of serum group I and group II pepsinogens in normal control subjects and patients with various disorders. Clin Chim Acta 1982;126:183-91.
19. 19 Konishi N, Matsumoto K, Hiasa Y, et al. Tissue and serum pepsinogen I and II in gastric cancer identified using immunohistochemistry and rapid ELISA. J Clin Pathol 1995;48:364-7.
20. 20 Matsumoto K, Hashimoto K, Samori T, et al. Clinical significance of the measurement of serum pepsinogen group I and II by enzyme-linked immunosorbent assay. Japanese Journal of Clinical Pathology 1992;40:977-81. (In Japanese.)
21. 21 Stemmermann GN, Samloff IM, Nomura AM, et al. Serum pepsinogens I and II and stomach cancer. Clin Chim Acta 1987,163:191-8.
22. 22 Nishizawa Y. Investigation of mass survey for gastric cancer. Journal of Gastroenterological Mass Survey 1993;98:74-9. (In Japanese.)